Hangzhou Tigermed Consulting Co., Ltd Share Price OTC Markets
Equities
HNGZY
US41044T1088
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.2 USD | -4.55% |
|
-.--% | -.--% |
06-18 | Hangzhou Tigermed Consulting Co., Ltd Announces Executive Changes | CI |
06-14 | Tigermed Consulting Assures Normal Operations Amid Share Price Fluctuations | MT |
Sales 2024 * | 8.11B 1.12B 87.95B | Sales 2025 * | 9.01B 1.24B 97.78B | Capitalization | 39.77B 5.47B 432B |
---|---|---|---|---|---|
Net income 2024 * | 2.05B 282M 22.25B | Net income 2025 * | 2.47B 340M 26.77B | EV / Sales 2024 * | 4.09 x |
Net cash position 2024 * | 7.3B 1.01B 79.24B | Net cash position 2025 * | 7.8B 1.07B 84.63B | EV / Sales 2025 * | 3.55 x |
P/E ratio 2024 * |
20.9
x | P/E ratio 2025 * |
17.4
x | Employees | - |
Yield 2024 * |
1.02% | Yield 2025 * |
1.21% | Free-Float | 69.68% |
1 day | -4.55% |
![Extreme 4.2](/images/extremecours_fleche.png)
![Extreme 4.2](/images/extremecours_fleche.png)
![Extreme 4.2](/images/extremecours_fleche.png)
![Extreme 4.2](/images/extremecours_fleche.png)
Managers | Title | Age | Since |
---|---|---|---|
Xiao Chun Cao
CEO | Chief Executive Officer | 55 | 31/12/04 |
Hao Wu
PSD | President | 56 | 31/12/19 |
Xiao Ping Ye
CHM | Chairman | 61 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Xiao Chun Cao
CEO | Chief Executive Officer | 55 | 31/12/04 |
Bing Hui Zhang
CHM | Chairman | 61 | 27/04/20 |
Xiao Ping Ye
CHM | Chairman | 61 | - |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+38.36% | 52.5B | |
+36.73% | 39.31B | |
-8.63% | 39.01B | |
+25.46% | 28.2B | |
-11.17% | 26.57B | |
+11.44% | 26.2B | |
+45.09% | 14.15B | |
+32.93% | 12.62B | |
-5.30% | 11.74B |
- Stock Market
- Equities
- 300347 Stock
- HNGZY Stock